260 related articles for article (PubMed ID: 27374471)
1. C-Jun N-terminal kinase signalling pathway in response to cisplatin.
Yan D; An G; Kuo MT
J Cell Mol Med; 2016 Nov; 20(11):2013-2019. PubMed ID: 27374471
[TBL] [Abstract][Full Text] [Related]
2. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance.
Brozovic A; Osmak M
Cancer Lett; 2007 Jun; 251(1):1-16. PubMed ID: 17125914
[TBL] [Abstract][Full Text] [Related]
3. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance.
Brozovic A; Fritz G; Christmann M; Zisowsky J; Jaehde U; Osmak M; Kaina B
Int J Cancer; 2004 Dec; 112(6):974-85. PubMed ID: 15386344
[TBL] [Abstract][Full Text] [Related]
4. Effects of sodium selenite on c-Jun N-terminal kinase signalling pathway induced by oxidative stress in human chondrocytes and c-Jun N-terminal kinase expression in patients with Kashin-Beck disease, an endemic osteoarthritis.
Dai X; Li Y; Zhang R; Kou Y; Mo X; Cao J; Xiong Y
Br J Nutr; 2016 May; 115(9):1547-55. PubMed ID: 26948765
[TBL] [Abstract][Full Text] [Related]
5. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair.
Hayakawa J; Depatie C; Ohmichi M; Mercola D
J Biol Chem; 2003 Jun; 278(23):20582-92. PubMed ID: 12663670
[TBL] [Abstract][Full Text] [Related]
6. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells.
Yu W; Shun MC; Anderson K; Chen H; Sanders BG; Kline K
Apoptosis; 2006 Oct; 11(10):1813-23. PubMed ID: 16850165
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of JNK/c-Jun-ATF2 Overcomes Cisplatin Resistance in Liver Cancer through down-Regulating Galectin-1.
Yang F; Li M; Xu D; Jiang Z; Jiang H; Xiao Y; Mei C; Yang M; Chen C; Zhou B; He B; Shan H; Pang P; Li D
Int J Biol Sci; 2023; 19(8):2366-2381. PubMed ID: 37215991
[TBL] [Abstract][Full Text] [Related]
8. JNK- and Akt-mediated Puma expression in the apoptosis of cisplatin-resistant ovarian cancer cells.
Zhao Z; Wang J; Tang J; Liu X; Zhong Q; Wang F; Hu W; Yuan Z; Nie C; Wei Y
Biochem J; 2012 Jun; 444(2):291-301. PubMed ID: 22394200
[TBL] [Abstract][Full Text] [Related]
9. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines.
Mikami T; Koyama T; Koyama T; Imakiire A; Yamamoto K; Furuhata M; Toyota H; Mizuguchi J
Anticancer Res; 2006; 26(2A):1153-60. PubMed ID: 16619517
[TBL] [Abstract][Full Text] [Related]
10. Caspase inhibitors, but not c-Jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss.
Wang J; Ladrech S; Pujol R; Brabet P; Van De Water TR; Puel JL
Cancer Res; 2004 Dec; 64(24):9217-24. PubMed ID: 15604295
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
[TBL] [Abstract][Full Text] [Related]
12. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
Li F; Meng L; Zhou J; Xing H; Wang S; Xu G; Zhu H; Wang B; Chen G; Lu YP; Ma D
Biochem Biophys Res Commun; 2005 Oct; 335(4):1070-7. PubMed ID: 16105650
[TBL] [Abstract][Full Text] [Related]
13. Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3beta with p53.
Matsui Y; Watanabe J; Ikegawa M; Kamoto T; Ogawa O; Nishiyama H
Oncogene; 2008 Jul; 27(33):4603-14. PubMed ID: 18391982
[TBL] [Abstract][Full Text] [Related]
14. Differential regulation of c-Jun protein plays an instrumental role in chemoresistance of cancer cells.
Xia Y; Yang W; Bu W; Ji H; Zhao X; Zheng Y; Lin X; Li Y; Lu Z
J Biol Chem; 2013 Jul; 288(27):19321-9. PubMed ID: 23678002
[TBL] [Abstract][Full Text] [Related]
15. Galloyl benzamide-based compounds modulating tumour necrosis factor α-stimulated c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signalling pathways.
Leo V; Stefanachi A; Nacci C; Leonetti F; de Candia M; Carotti A; Altomare CD; Montagnani M; Cellamare S
J Pharm Pharmacol; 2015 Oct; 67(10):1380-92. PubMed ID: 26078032
[TBL] [Abstract][Full Text] [Related]
16. Tubeimoside I sensitizes cisplatin in cisplatin-resistant human ovarian cancer cells (A2780/DDP) through down-regulation of ERK and up-regulation of p38 signaling pathways.
Liu HZ; Yu C; Yang Z; He JL; Chen WJ; Yin J; Li WM; Liu HT; Wang YX
Mol Med Rep; 2011; 4(5):985-92. PubMed ID: 21687949
[TBL] [Abstract][Full Text] [Related]
17. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.
Kim M; Yan Y; Kortum RL; Stoeger SM; Sgagias MK; Lee K; Lewis RE; Cowan KH
Cancer Res; 2005 May; 65(10):3986-92. PubMed ID: 15899786
[TBL] [Abstract][Full Text] [Related]
18. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines.
Watanabe J; Nishiyama H; Matsui Y; Ito M; Kawanishi H; Kamoto T; Ogawa O
Oncogene; 2006 Apr; 25(17):2500-8. PubMed ID: 16518417
[TBL] [Abstract][Full Text] [Related]
19. TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells.
Zhang P; Liu SS; Ngan HY
PLoS One; 2012; 7(8):e42985. PubMed ID: 22900074
[TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway.
Ohtsuka T; Buchsbaum D; Oliver P; Makhija S; Kimberly R; Zhou T
Oncogene; 2003 Apr; 22(13):2034-44. PubMed ID: 12673208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
